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Many untreatable blinding diseases involve degeneration of retinal pigmented epithelial (RPE) cells, which
has prompted exploration of the therapeutic potential of human-pluripotent-stem-cell-derived RPE. The first
safety trials reported in The Lancet of embryonic-stem-cell-derived RPE cell transplants indicate no serious
adverse outcomes and encourage further investigation.In a recent issue of The Lancet, Schwartz
et al. (2014) reported on progress in phase
I/II clinical trials transplanting embryonic
stem cell (ESC)-derived retinal pigment
epithelial (RPE) cells in late-stage retinal
degenerative disease. As the first report
on the mid- to long-term safety of ESCs
in cell therapy for any disease, this study
is highly significant for the future develop-
ment of ESC-based therapies.
In the retina, RPE cells serve multiple
roles essential for the function and sur-
vival of the light-sensitive photoreceptor
cells; they form a polarized monolayer
(on Bruch’s basement membrane) be-
tween the blood supply of the choroid
and the overlying photoreceptor cells.
Degeneration of RPE cells is involved in
many untreatable blinding eye diseases,
including atrophic age-related macular
degeneration (AMD), which is the most
common cause of sight impairment in
industrialized countries, and Stargardt
disease, which is the most common
cause of inherited sight loss. The etiology
of AMD is complex and polygenic with
variant components of the complement
cascade increasing the risk of disease,
whereas Stargardt disease is usually
caused by autosomal recessive muta-
tions in the ABCA4 gene, an ATP-binding
cassette transporter essential for the
removal of potentially toxic retinoid com-
pounds from photoreceptor cells (Quazi
and Molday, 2014).
The overarching aim of RPE cell trans-
plantation therapy is to delay or prevent
the progressive loss of photoreceptor
cells by restoring healthy RPE function.
Preclinical studies indicating the efficacy
of RPE transplantation are limited, partly
due to the lack of animal models forAMD, although there is some evidence
that healthy RPE may extend the survival
of photoreceptor cells and preserve mac-
ular function, for example, following trans-
location of autologous RPE in patients
(van Zeeburg et al., 2012). In recent years
remarkable progress has been made in
establishing protocols for the generation
of retinal cells from human pluripotent
stem cells (hPSCs) (Nakano et al., 2012).
ESC and induced pluripotent stem cells
(iPSC) cultures can generate large
numbers of RPE cells that form polarized
monolayers and perform many of the
functions of primary RPE such as rod
photoreceptor outer segment phagocy-
tosis (Buchholz et al., 2009; Ramsden
et al., 2013; Kamao et al., 2014). The po-
tential for therapeutic application of these
cells is widely recognized, though the
rationale for which disease context ESC-
RPE cells might provide most benefit is
a topic of debate. Several studies have
evaluated ESC-RPE and iPSC-RPE using
the Royal College of Surgeons (RCS) rat
model of retinal degeneration, which har-
bors a mutation in the Mertk gene essen-
tial for outer segment phagocytosis, and
have showed that subretinal injection of
RPE can promote photoreceptor survival
(Lu et al., 2009; Ramsden et al., 2013),
though the mechanism by which this
occurs has not been entirely resolved
and may be independent of replacement
of RPE function.
A number of clinical trials investigating
the safety of ESC-RPE and iPSC-RPE
transplantation are now underway or
planned (Ramsden et al., 2013). Schwartz
et al., funded by Advanced Cell Technol-
ogy (ACT), reported previously the prelim-
inary findings in two patients of safety andCell Stem Cell 15,tolerability studies (Schwartz et al., 2012)
and now describe the mid- to longer-
term follow-up (Schwartz et al., 2014).
They report the outcomes in nine patients
with AMD and nine patients with Star-
gardt’s macular dystrophy receiving sub-
retinal transplants in one eye of 50,000,
100,000, or 150,000 ESC-RPE cells. All
patients had end-stage disease with
vision ranging from 20/200 (severe vision
loss) to hand motion (near blindness).
Because the loss of photoreceptor cells
is at an advanced stage, the likelihood of
recovery of vision in this population is
low. In Stargardt disease, RPE transplan-
tation might theoretically prolong photo-
receptor survival, though it cannot be
expected to correct the underlying photo-
receptor gene defect.
The ESC-derived RPE cell preparation,
classified as a xenotransplantation prod-
uct because it involved animal cell cocul-
ture, was previously described (Schwartz
et al., 2012). It involved differentiation
to produce pigmented RPE patches of
cells that were cryopreserved before
direct subretinal injection as a cell sus-
pension at a preselected transition zone
between the central atrophic region and
surrounding relatively healthy retina.
Other studies plan to introduce cells sup-
ported on substrate that mimics Bruch’s
membrane, rather than as a suspension,
which may enhance the generation of an
RPE monolayer in vivo. Schwartz et al.
report a number of adverse surgical
events, including RPE defects, persistent
subretinal injection bleb, acute postoper-
ative endophthalmitis, and significant
cataract in four patients. These complica-
tions were considered by the authors to
be in line with the risks of vitreoretinalNovember 6, 2014 ª2014 Elsevier Inc. 537
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related to immune suppression were
also reported. However, there were
no ocular or systemic safety concerns
attributable to the transplanted ESC-
derived RPE cells themselves, such as
significant immune reactions, uncon-
trolled differentiation, hyperproliferation,
or tumor formation.
The safety of subretinal transplantation
of ESC-RPE cells is also supported by the
visual acuity findings. The acuity of the
treated eyewasmaintained in themajority
of participants with both AMD and Star-
gardt disease who did not develop cata-
ract. In fact, the median improvement
from baseline of visual acuity measured
in those patients with AMD who did not
develop cataract was greater in the
treated than untreated eyes. It is widely
acknowledged that the reliability of visual
acuity assessment at low levels of vision is
relatively poor and the authors point to the
possible influence of placebo effect,
examiner bias, and other non-cell-spe-
cific effects of surgery. Nevertheless,
these initial results provide valuable reas-
surance that transplantation of ESC-RPE
cells appears well tolerated, encourage
further investigation, and will help accel-
erate progress in other planned trials of
hPSCs for tissue repair.
The ideal outcome would be for the
transplanted RPE cells to attach to
Bruch’s membrane, align correctly to
form a monolayer extending into the atro-
phic regions between the neural retina
and the vascular choriocapillaris, and
function properly (e.g., perform efficient
phagocytosis, secretion, and transport
functions) so that further photoreceptor
damage may be limited. It is however
very difficult to evaluate transplanted cell
behavior without cell labeling techniques
using existing in vivo imaging technology
because it is not possible to firmly distin-538 Cell Stem Cell 15, November 6, 2014 ª2guish the transplanted ESC-derived cells
from the endogenous cells of the recip-
ient. Schwartz et al. report the develop-
ment in the majority of eyes of patches
of subretinal hyperpigmentation, consis-
tent with successful transplantation and
suggestive of a layer of cells lining Bruch’s
membrane. They rightly caution, however,
that the hyperpigmentation does not
correlate with changes in visual acuity
and may not correspond to transplanted
RPE cells that cannot be distinguished
noninvasively from surviving recipient
RPE cells. Optical coherence tomography
(OCT) imaging demonstrates areas of
increased signal but cannot determine
whether the transplanted cells survive,
and the variability on fundus autofluores-
cence imaging is open to interpretation.
In future studies, higher-resolution cellular
imaging, for example through the use of
adaptive optics techniques, may shed
more light on the impact of ESC-RPE
cell transplantation on retinal structure.
These latest results indicate treatment of
patients at earlier stages of disease who
are likely to still have photoreceptors to
preserve. Additional preclinical studies in
animal models using genetic cell labeling
techniques to compare the potential of
cells delivered as a dissociated suspen-
sion, or on support matrices, to form func-
tional RPE monolayers and preserve
photoreceptors will be important to guide
the development of future trials. Because
systemic immunosuppression is undesir-
able, the use of autologous or HLA-
matched hPSCs offers a promising future
option (Wright et al., 2014). Ultimately,
what will matter most is the impact of
intervention on retinal function. In this
early study the authors report no clear
impact of transplantation on reading
speed or conventional static perimetry.
In future studies more sophisticated mea-
sures of retinal sensitivity, such as micro-014 Elsevier Inc.perimetry, may help determine the effect
of intervention on retinal function across
the transplanted area and identify
the relevance of the hyperpigmentation
observed.
In summary, this study represents an
important and promising first step on the
pathway toward stem cell therapies being
developed for the treatment of incurable
blindness. Lastly, we should applaud the
patients for their participation in this pio-
neering work.
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